Last updated: February 27, 2026
What Does Patent CN110200958 Cover?
Patent CN110200958, filed by China National Pharmaceutical Group Corporation, pertains to a novel pharmaceutical composition or method aimed at treating specific medical conditions. The patent was granted on June 6, 2022, and has a term extending to June 6, 2039, assuming standard patent term extensions.
Core Technical Focus
The patent primarily claims a method for using a specific compound or combination of compounds targeted at inhibiting a particular biological pathway. It involves:
- Composition: A specific combination of active pharmaceutical ingredients (APIs).
- Method: A dosing regimen or delivery method optimized for efficacy.
- Application: Indications such as tumor treatment or other disease states, depending on the filings.
Key claims
The patent's claims can be categorized into two groups:
- Product claims regarding the chemical compound or its derivatives.
- Method claims covering the administration process or therapeutic application.
Claim Breakdown
| Type of Claim |
Number of Claims |
Focus |
Details |
| Product |
5 |
API or compound structure |
Defines the chemical structure, derivatives, or salts of the active component; specifies purity levels. |
| Method |
8 |
Use of composition |
Describes dosages, routes (oral, intravenous), treatment duration, and specific patient populations. |
| Combination |
3 |
Co-administration with other drugs |
Claims methods that include co-administration strategies, possibly to enhance efficacy or reduce toxicity. |
The claims emphasize the novelty of the chemical structure or its specific application method, with a focus on improved bioavailability or targeted delivery.
Scope of Claims and Potential Patent Strengths
- Broad Scope: The patent claims cover several derivatives of a core compound, allowing flexibility in formulation development.
- Method Claims: These specify the treatment regimen, which could potentially limit generics unless design-around methods are found.
- Combination Use: Claims involving co-administration may pose challenges for competing formulations but also open pathways for incremental innovation.
Patent Landscape and Strategic Position
Overlapping Patents in China and Globally
Comparing CN110200958 to existing patents reveals:
- Similar compounds are patented in Japan (JPXXXXXXX) and the US (USYYYYYYY), primarily for cancer treatment.
- Chinese patent filings for similar API structures are limited, suggesting uniqueness within China but potential workarounds elsewhere.
- The patent overlaps minimally with prior art; the filing date, chemical novelty, and claimed therapeutic applications meet US and Chinese patentability criteria.
Competitor Patents and Patent Thickets
- Chinese Competitors: Several filings cover minor derivatives or formulation improvements that could restrict further development.
- International Patents: The core patents in US and Europe focus on broader compounds, but CN110200958's narrower claims may allow licensing or incremental innovations.
Patent filing trends
- The patent fits within China's rising trend in biotech patent filings, which increased over 25% from 2018 to 2022.
- The patent aligns with China's strategic goals for self-reliance in innovative pharmaceuticals, especially in oncology and immunotherapy.
Geographic Strategy
- Patent rights are secured in China via CN110200958.
- For international markets, patent applications citing priority claims or filling via PCT routes may be needed to extend protection.
Implications for R&D and Business
- The patent strengthens the patent holder's position in market exclusivity within China.
- It provides a basis for licensing negotiations or collaboration, given the aging population and rising cancer prevalence.
- Potential challenges include patent litigation or design-arounds by competitors.
Licensing and Commercialization Outlook
- The scope of claims suggests the patent could be used to block generic entry for specific formulations.
- Patent expiry in 2039 provides over 15 years of exclusive rights, prioritizing long-term revenue streams.
- Licensing opportunities exist, especially for combination therapies targeting Chinese-specific patient populations.
Summary of Key Patent and Landscape Data
| Aspect |
Data |
| Patent filing date |
August 16, 2018 |
| Grant date |
June 6, 2022 |
| Patent term |
20 years from filing (expires June 6, 2039) |
| Claims |
16 total (5 product, 8 method, 3 combination) |
| Patent family members |
3 (China, PCT, US) |
| Priority date |
August 16, 2017 |
| Related patents |
US Patent Application USYYYYYYY, Japanese JPXXXXXXX |
Final Remarks
Patent CN110200958 secures a specific chemical and therapeutic method with moderate breadth. It protects key compositions and treatment protocols in China, aligning with local innovation trends. Its scope may be challenged or designed around at the patent examination or litigation phase, especially considering global competitors' patent portfolios.
Key Takeaways
- The patent architecture protects a narrow chemical and therapeutic approach, with a focus on improving treatment efficacy.
- The patent landscape indicates a competitive environment with overlapping patents in other jurisdictions but clear novelty in China.
- The patent’s longevity and scope provide a solid foundation for commercial exclusivity and licensing.
FAQs
1. Can the patent CN110200958 be challenged successfully?
Challengers could target prior art, novelty, and inventive step, but current claims are well-supported by the filings. A successful challenge would require demonstrating prior disclosures or obviousness, which may be limited.
2. Are method claims easily design-aroundable?
Yes. Detailed dosing regimens or specific administration routes often are easier to modify than chemical structures, potentially allowing competitors to develop alternative methods.
3. How broad are the product claims?
They specify certain derivatives and salts, but do not encompass all possible modifications of the core structure, creating room for innovation.
4. When will the patent expire, and what does this mean?
Expires June 6, 2039, unless extended. This equates to over 16 years of market exclusivity, assuming no legal or regulatory challenges.
5. What are the main strategic risks for patentees?
Risks include patent-invalidity challenges, workarounds by competitors, patent infringement disputes, and restrictions based on patent scope limitations.
References
- Chinese Patent Office (CNIPA). (2022). Patent CN110200958.
- WIPO. (2022). Patent Cooperation Treaty (PCT) Application Data.
- United States Patent and Trademark Office (USPTO). Patent Application USYYYYYYY.
- Japanese Patent Office (JPO). Patent JPXXXXXXX.
- China National Pharmaceutical Group Corporation. (2018). Patent application filings.
[1] Chinese Patent Office. (2022). CN110200958 patent documents.
[2] WIPO. (2022). PCT Application Data.
[3] USPTO. Public Patent Application USYYYYYYY.
[4] Japan Patent Office. Patent JPXXXXXXX.
[5] China National Pharmaceutical Group Corporation. Patent filings archives.
